Guardia Valenzuela, Cristina (Date of defense: 2019-12-19)
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el ...
Soria Jiménez, Luis (Date of defense: 2023-02-17)
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...
García Parra, Jetzabel (Date of defense: 2012-06-21)
Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of ...